Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Epigenetic Reprogramming in Relapse/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-06-24
- Target Recruit Count
- 37
- Registration Number
- NCT03263936
- Locations
- 🇺🇸
National Cancer Institute, Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 200
- Registration Number
- NCT03252457
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT03250962
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 37
- Registration Number
- NCT03240211
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sclnow Biotechnology Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03184935
- Locations
- 🇨🇳
Inner Mongolia International Mongolian Hospital, Hohhot, Inner Mongolia, China
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT03146871
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients with Recurrent or Refractory Leukemia
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03132454
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03113071
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Jeans Hospital, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.